Vaccine value profile for cytomegalovirus

Boppana, Suresh B.; van Boven, Michiel; Britt, William J.; Gantt, Soren; Griffiths, Paul D.; Grosse, Scott D.; Hyde, Terri B.; Lanzieri, Tatiana M.; Mussi-Pinhata, Marisa M.; Pallas, Sarah E.; Pinninti, Swetha G.; Rawlinson, William D.; Ross, Shannon A.; Vossen, Ann C.T.M.; Fowler, Karen B.

doi:10.1016/j.vaccine.2023.06.020

Cited by 5 publications

(4 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 158 Although a licensed CMV vaccine is not available, several candidate vaccines are currently in various stages of development. 159 In a phase 2 trial of an MF59-adjuvanted CMV glycoprotein B subunit vaccine in CMV seronegative women enrolled in the postpartum period, provided approximately 50% protection against acquiring primary infection. 160 , 161 However, the efficacy of the vaccine waned during the first 15 months of the study.…”

Section: Preventionmentioning

confidence: 99%

CMV-induced Hearing Loss

Maheshwari,

Singh,

Boppana

2024

Newborn

View full text Add to dashboard Cite

Congenital cytomegalovirus (cCMV) infection is the most common fetal viral infection and contributes to about 25% of childhood hearing loss by the age of 4 years. It is the leading nongenetic cause of sensorineural hearing loss (SNHL). Infants born to seroimmune mothers are not completely protected from SNHL, although the severity of their hearing loss may be milder than that seen in those whose mothers had a primary infection. Both direct cytopathic effects and localized inflammatory responses contribute to the pathogenesis of cytomegalovirus (CMV)-induced hearing loss. Hearing loss may be delayed onset, progressive or fluctuating in nature, and therefore, a significant proportion will be missed by universal newborn hearing screening (NHS) and warrants close monitoring of hearing function at least until 5–6 years of age. A multidisciplinary approach is required for the management of hearing loss. These children may need assistive hearing devices or cochlear implantation depending on the severity of their hearing loss. In addition, early intervention services such as speech or occupational therapy could help better communication, language, and social skill outcomes. Preventive measures to decrease intrauterine CMV transmission that have been evaluated include personal protective measures, passive immunoprophylaxis and valacyclovir treatment during pregnancy in mothers with primary CMV infection. Several vaccine candidates are currently in testing and one candidate vaccine in phase 3 trials. Until a CMV vaccine becomes available, behavioral and educational interventions may be the most effective strategy to prevent maternal CMV infection.

show abstract

Section: Preventionmentioning

confidence: 99%

CMV-induced Hearing Loss

Maheshwari,

Singh,

Boppana

2024

Newborn

View full text Add to dashboard Cite

show abstract

“…Similarly, even if a vaccine does not prevent infection, it may mitigate negative outcomes. Despite ongoing vaccine development for HCMV, however, no licensed vaccine for HCMV is currently available [1], although development and distribution of a vaccine for HCMV would result in significant progress in public health. In fact, the US National Institute of Medicine considers the development of a vaccine for HCMV of critical importance [1].…”

Section: Perspectives and Conclusionmentioning

confidence: 99%

“…A beta herpesvirus [1], human cytomegalovirus (HCMV) is a common and widely distributed infectious disease. The estimated overall average worldwide prevalence of HCMV is approximately 83 percent, although there is significant regional variability [2], with Asia, Africa, and South America in general having higher HCMV seroprevalences than western Europe and North America [3].…”

Section: Introductionmentioning

confidence: 99%

“…However, most people infected with HCMV do not experience distinct symptoms, may be asymptomatic [4], or may present with nonspecific symptoms seen in other viral illnesses such as those associated with mononucleosis including fever, headache, and fatigue [5]. HCMV infection may occur at any age and can be present at birth [1]. Further, HCMV has been associated with a range of diseases including cardiovascular disease and possibly cancer [5] and may aggravate or even increase risk for autoimmunity [6].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Human Cytomegalovirus Infection and Neurocognitive and Neuropsychiatric Health

Gale,

Farrer,

Erbstoesser

et al. 2024

Pathogens

View full text Add to dashboard Cite

A common infection, human cytomegalovirus (HCMV) has been associated with a variety of human diseases, including cardiovascular disease and possibly certain cancers. HCMV has also been associated with cognitive, psychiatric, and neurological conditions. Children with congenital or early-life HCMV are at risk for microcephaly, cerebral palsy, and sensorineural hearing loss, although in many cases sensorineural loss may resolve. In addition, HCMV can be associated with neurodevelopmental impairment, which may improve with time. In young, middle-aged, and older adults, HCMV has been adversely associated with cognitive function in some but not in all studies. Research has linked HCMV to Alzheimer’s and vascular dementia, but again not all findings consistently support these associations. In addition, HCMV has been associated with depressive disorder, bipolar disorder, anxiety, and autism-spectrum disorder, although the available findings are likewise inconsistent. Given associations between HCMV and a variety of neurocognitive and neuropsychiatric disorders, additional research investigating reasons for the considerable inconsistencies in the currently available findings is needed. Additional meta-analyses and more longitudinal studies are needed as well. Research into the effects of antiviral medication on cognitive and neurological outcomes and continued efforts in vaccine development have potential to lower the neurocognitive, neuropsychiatric, and neurological burden of HCMV infection.

show abstract